1. Home
  2. About NIDDK
  3. Staff Directory
  4. Jenny E. Blau, M.D.

Jenny E. Blau, M.D.

Photo of Dr. Jenny Blau
Scientific Focus Areas: Clinical Research, Cancer Biology, Genetics and Genomics

Professional Experience

  • North American Neuroendocrine Tumor Society, 2018
  • Endocrine Society, 2012
  • American Diabetes Association, 2012
  • American College of Physicians, 2010
  • Endocrine and Metabolism Fellowship, Inter-Institute Endocrine Training Program, NIH 2012-2015
  • Internal Medicine Residency, Georgetown University Hospital, 2009-2012
  • M.D., Georgetown University School of Medicine, 2009

Current Research

Primary hyperparathyroidism is a common endocrine disorder with a prevalence estimated between 1- 36 per 1000 people. Primary hyperparathyroidism is almost always caused by parathyroid tumors, which can occur as a solitary adenoma (~85%), multi-gland disease (~15%), or parathyroid carcinoma (<1%). Our branch has a long-standing interest in the pathogenesis and clinical spectrum of hyperparathyroidism in the context of inherited diseases such as familial isolated hyperparathyroidism, multiple endocrine neoplasia type 1, hyperparathyroidism-jaw tumor syndrome (HPT-JT) as well as parathyroid cancer. In addition to understanding the natural clinical history of these disorders, research studies focus on the genetics, development of novel diagnostic tools including circulating biomarkers, nuclear medicine imaging techniques, as well as the development of therapeutic agents modeled from in vivo and in vitro studies in hyperparathyroidism animal models. Our research also focuses on the development of novel diagnostic and therapeutic interventions for pancreatic neuroendocrine tumors.

Select Publications

Prospective Study of a Novel, Radiation-Free, Reduced-Intensity Bone Marrow Transplantation Platform for Primary Immunodeficiency Diseases.
Dimitrova D, Gea-Banacloche J, Steinberg SM, Sadler JL, Hicks SN, Carroll E, Wilder JS, Parta M, Skeffington L, Hughes TE, Blau JE, Broadney MM, Rose JJ, Hsu AP, Fletcher R, Nunes NS, Yan XY, Telford WG, Kapoor V, Cohen JI, Freeman AF, Garabedian E, Holland SM, Lisco A, Malech HL, Notarangelo LD, Sereti I, Shah NN, Uzel G, Zerbe CS, Fowler DH, Gress RE, Kanakry CG, Kanakry JA.
Biol Blood Marrow Transplant (2020 Jan) 26:94-106. Abstract/Full Text
Clinical presentation and management of primary ovarian neuroendocrine tumor in multiple endocrine neoplasia type 1.
Jhawar S, Lakhotia R, Suzuki M, Welch J, Agarwal SK, Sharretts J, Merino M, Ahlman M, Blau JE, Simonds WF, Del Rivero J.
Endocrinol Diabetes Metab Case Rep (2019 Aug 20) 2019. Abstract/Full Text
View More Publications

Research in Plain Language

Hyperparathyroidism is a disorder in which the parathyroid glands secrete too much parathyroid hormone, resulting in high concentrations of calcium circulating in the blood. This is most commonly caused by tumors of the parathyroid glands. Usually, these tumors occur without a genetic cause, but sometimes this can occur because it is inherited from a family member. The purpose of our research is to better understand the genetic causes of hyperparathyroidism and to develop new ways to help patients in the diagnosis, management, and/or treatment of this condition.

We study inherited syndromes that are associated with hyperparathyroidism, including multiple endocrine neoplasia type 1 (MEN1). This syndrome also causes neuroendocrine tumors of the pituitary and pancreas, among other locations. Our research aims to translate molecular mechanisms by which this inherited syndrome can lead to neoplasia (tumors) into improved treatments for patients.